ABSTRACT
In order to obtain fundamental information on the disposition of hypnotics into hair after a single oral dose the quantitative hair analysis of triazolam (TZ), etizolam (EZ), flunitrazepam (FNZ), nitrazepam (NZ) and zolpidem (ZP) have been performed using a validated LC-MS/MS procedure. Hair specimens (straight, black) were collected from three subjects about one month and three months after a single 0.25 mg dose of TZ, 1 mg of EZ, 2 mg of FNZ, 5 mg of NZ and 10 mg of ZP tartrate. The subjects ingested just one out of five different hypnotics on each day, each of five days in turn. All ingested hypnotics have been detected in hair from each subject both one month and three months after intake, and their concentrations were in the range of 0.023-0.043 pg/hair strand (0.077-0.36 pg/mg) for TZ, 0.11-0.63 pg/hair strand (0.44-5.2 pg/mg) for EZ, 0.14-2.6 pg/hair strand (0.56-22 pg/mg) for FNZ, 0.33-1.7 pg/hair strand (1.3-17 pg/mg) for NZ and 20-40 pg/hair strand (120-270 pg/mg) for ZP. For FNZ and NZ, not only the parent drugs but also their metabolites, 7-amino-FNZ and 7-amino-NZ, were detected in the range of 2.3-9.2 pg/hair strand (9.2-82 pg/mg) and 2.4-9.1 pg/hair strand (8.0-55 pg/mg), respectively. The calculated incorporation ratios into hair against the dose were found to exhibit similarity between the four benzodiazepines. This finding suggests the ability to apply these quantitative data to approximately estimating the amounts of other benzodiazepines, which have similar chemical structures, in hair although it should be noted that the amounts of drugs in hair varies considerably depending on the hair color. On the other hand, the incorporation ratio of ZP showed 15-29 times higher than that of TZ, indicating that lipophilic ZP was more likely to incorporate into hair than benzodiazepines. In addition, the application of the present data to a drug-facilitated sexual assault was shown.
Subject(s)
Hair/chemistry , Hypnotics and Sedatives/analysis , Adult , Asian People , Chromatography, Liquid , Crime , Diazepam/administration & dosage , Diazepam/analogs & derivatives , Diazepam/analysis , Female , Flunitrazepam/administration & dosage , Flunitrazepam/analysis , Forensic Toxicology , Humans , Hypnotics and Sedatives/administration & dosage , Male , Mass Spectrometry , Nitrazepam/administration & dosage , Nitrazepam/analysis , Substance Abuse Detection , Triazolam/administration & dosage , Triazolam/analysis , Zolpidem/administration & dosage , Zolpidem/analysisABSTRACT
Clinical induction liability is assessed with human hepatocytes. However, underpredictions in the magnitude of clinical induction have been reported. Unfortunately, in vivo studies in animals do not provide additional insight because of species differences in drug metabolizing enzymes and their regulatory pathways. To circumvent this limitation, transgenic animals expressing human orthologs were developed. The aim of this work was to investigate the utility of mouse models expressing human orthologs of pregnane X receptor, constitutive androstane receptor, and CYP3A4/7 (Tg-Composite) in evaluating clinical induction. Rifampin, efavirenz, and pioglitazone, which were employed to represent strong, moderate, and weak inducers, were administered at multiple doses to Tg-Composite animals. In vivo CYP3A activity was monitored by measuring changes in the exposure of the CYP3A probe substrate triazolam. After the in vivo studies, microsomes were prepared from their livers to measure changes of in vitro CYP3A4 activity. In both in vivo and in vitro, distinction of clinic induction was recapitulated as rifampin yielded the greatest inductive effect followed by efavirenz and pioglitazone. Interestingly, with rifampin, in vivo CYP3A activity was approximately 4-fold higher than in vitro activity. Conversely, there was no difference between in vivo and in vitro CYP3A activity with efavirenz. These findings are consistent with the report that, although rifampin exhibits differential inductive effects between the intestines and liver, efavirenz does not. These data highlight the promise of transgenic models, such as Tg-Composite, to complement human hepatocytes to enhance the translatability of clinical induction as well as become a powerful tool to further study mechanisms of drug disposition. SIGNIFICANCE STATEMENT: Underprediction of the magnitude of clinical induction when using human hepatocytes has been reported, and transgenic models may improve clinical translatability. The work presented here showcases the human orthologs of pregnane X receptor, constitutive androstane receptor, and CYP3A4/7 model, which was able to recapitulate the magnitude of clinical induction and to differentiate tissue-dependent induction observed with rifampin but not with efavirenz. These results not only foreshadow the potential application of such transgenic models in assessing clinical induction but also in further investigation of the mechanism of drug disposition.
Subject(s)
Cytochrome P-450 CYP3A Inducers/pharmacokinetics , Alkynes/administration & dosage , Alkynes/pharmacokinetics , Animals , Benzoxazines/administration & dosage , Benzoxazines/pharmacokinetics , Constitutive Androstane Receptor/genetics , Constitutive Androstane Receptor/metabolism , Cyclopropanes/administration & dosage , Cyclopropanes/pharmacokinetics , Cytochrome P-450 CYP3A/genetics , Cytochrome P-450 CYP3A/metabolism , Cytochrome P-450 CYP3A Inducers/administration & dosage , Drug Evaluation, Preclinical/methods , Drug Interactions , Feasibility Studies , Female , Humans , Mice , Mice, Transgenic , Microsomes, Liver , Pioglitazone/administration & dosage , Pioglitazone/pharmacokinetics , Pregnane X Receptor/genetics , Pregnane X Receptor/metabolism , Rifampin/administration & dosage , Rifampin/pharmacokinetics , Species Specificity , Triazolam/administration & dosage , Triazolam/pharmacokineticsABSTRACT
PURPOSE: To determine whether patient satisfaction with oral sedation is noninferior to intravenous sedation for cataract surgery. DESIGN: Prospective, randomized, double-masked clinical trial. PARTICIPANTS: A volunteer sample of patients 18 years or older from diverse backgrounds scheduled for cataract surgery. Patients who were allergic to benzodiazepines, older than 70 years with a failed delirium screening questionnaire, pregnant or nursing, using a medication inhibiting cytochrome 450 3A, or intoxicated on the day of surgery were excluded. METHODS: Patients were randomized to receive either oral triazolam with intravenous placebo or intravenous midazolam with oral placebo before surgery. MAIN OUTCOMES MEASURES: The primary outcome was patient satisfaction, measured by a survey administered on postoperative day 1. Secondary outcomes included surgeon and anesthesia provider satisfaction, need for supplemental anesthesia, and surgical complications. RESULTS: Among the 85 patients (42 men [49.4%]; mean age, 65.8 years; standard deviation, 9.5 years) completing the study, the mean satisfaction score was 5.34±0.63 (range, 3.75-6) in the oral sedation group and 5.40±0.52 (range, 4-6) in the intravenous group. With an a priori noninferiority margin of 0.5 and a difference in mean scores between the 2 groups of 0.06 (1-tailed 95% confidence interval [CI], -infinity to 0.27), our results demonstrate noninferiority of oral sedation with a P value of 0.0004. Surgeon and anesthesia provider satisfaction was similar between the 2 groups. Intraoperative complications occurred in 16.7% in the oral group and 9.3% in the intravenous group (difference, 7.4%; 95% CI, -6.9% to 21.6%; P = 0.31). The only major intraoperative complication-a posterior capsular tear-occurred in the intravenous group. Eight patients in the oral group (19.0%) and 3 in the intravenous group (7.0%) received supplemental intravenous sedation (difference, 12.1%; 95% CI, -2.0% to 26.2%; P = 0.097). CONCLUSIONS: The use of oral sedation in cataract surgery has been suggested as a cost- and space-saving measure, potentially allowing the transition of some patients from an operating to procedure room or office-based setting. We report the noninferiority of oral compared with intravenous sedation for cataract surgery in a diverse patient population in terms of patient satisfaction.
Subject(s)
Conscious Sedation/methods , Hypnotics and Sedatives/administration & dosage , Lens Implantation, Intraocular , Midazolam/administration & dosage , Patient Satisfaction/statistics & numerical data , Phacoemulsification , Triazolam/administration & dosage , Administration, Oral , Aged , Anesthetics, Intravenous , Anesthetics, Local/administration & dosage , Double-Blind Method , Eye Pain/physiopathology , Eye Pain/prevention & control , Female , Humans , Male , Middle Aged , Pain Measurement , Prospective StudiesABSTRACT
1-Aminobenzotriazole (ABT) is a mechanism-based inactivator of major cytochrome P450 (CYP) enzymes, which is used in multiple mechanistic studies. The purpose was to evaluate the effect of 2 and 16-h pretreatment regimens of ABT on the exposures of triazolam in rat. Another objective was to evaluate the effect of ABT on gastric emptying of acetaminophen. Plasma area under the curve (AUC) of triazolam was increased by 101-fold and 81-fold for the rats pretreated with ABT at 2 and 16 h, respectively, compared to control rats. Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively. In the case of acetaminophen, where Tmax was not delayed, the mean absorption time (MAT) in control, 2 and 16 h ABT pretreatment groups were 0.3, 4.6 and 2.9 h, respectively, suggesting delayed absorption. This hypothesis was further supported by GastroPlusTM simulation. In summary, extent of triazolam absorption was increased to a similar extent with both 2 and 16 h ABT pretreatment regimens, suggesting that either of the regimen can be used to increase parent exposures in rat. With ABT pretreatment, delayed absorption of triazolam and acetaminophen was observed, as suggested by delay in Tmax and MAT, respectively.
Subject(s)
Cytochrome P-450 Enzyme Inhibitors/pharmacology , Gastric Emptying/drug effects , Triazolam/pharmacokinetics , Triazoles/pharmacology , Acetaminophen/pharmacokinetics , Administration, Oral , Animals , Area Under Curve , Cytochrome P-450 Enzyme Inhibitors/administration & dosage , Cytochrome P-450 Enzyme System/metabolism , Male , Rats , Rats, Sprague-Dawley , Triazolam/administration & dosage , Triazoles/administration & dosageABSTRACT
OBJECTIVE: To assess the effects of hypnotics on prefrontal cortex activity in healthy subjects using near-infrared spectroscopy (NIRS) in a double-blind, placebo-controlled crossover trial. METHODS: Eighteen healthy males received acute doses of ramelteon (8 mg), triazolam (0.125 mg), or placebo in a predetermined randomization schedule, with a washout period of more than 1 week. All subjects performed a verbal fluency task during NIRS assessments at baseline and at 1 and 4 hr post-dose. The number of words correctly generated during the task (behavioral performance) and scores on the Stanford Sleepiness Scale (SSS) were also recorded at each test time. RESULTS: Compared with the placebo, triazolam (0.125 mg) significantly decreased oxyhemoglobin (oxy-Hb) concentration change in NIRS during the posttask period and significantly increased behavioral performance, whereas triazolam (0.125 mg) and ramelteon (8 mg) significantly increased SSS scores. CONCLUSIONS: The differential effects of two types of hypnotics on oxy-Hb change measured by NIRS were observed in acute dosing, suggesting that when assessing brain activity of patients with psychiatric disorders, researchers should consider how certain types of hypnotics can influence brain function. This would also provide useful information to clinicians when prescribing hypnotics suitable for their patients' conditions.
Subject(s)
Hypnotics and Sedatives/pharmacology , Indenes/pharmacology , Memory/drug effects , Prefrontal Cortex/drug effects , Triazolam/pharmacology , Adult , Cross-Over Studies , Double-Blind Method , Humans , Hypnotics and Sedatives/administration & dosage , Indenes/administration & dosage , Male , Memory/physiology , Oxyhemoglobins/drug effects , Prefrontal Cortex/diagnostic imaging , Prefrontal Cortex/physiology , Spectroscopy, Near-Infrared , Triazolam/administration & dosage , Young AdultABSTRACT
It has been reported that insomnia characterized by difficulty returning to sleep following a nocturnal awakening, otherwise defined as the middle-of-the-night (MOTN) insomnia, is a common form of insomnia in adults with growing prevalence by increasing age. The aim of this study is to evaluate the efficacy and safety of different dosages of triazolam in insomnia patients when taken after a MOTN awakening with difficulty returning to sleep. In this double-blind, randomized, parallel group study, 24 patients (mean age 41.00 ± 10.40, 10 female and 14 male) affected by MOTN insomnia were enrolled and randomized into three groups according to different dosages of triazolam: group A (0.0625 mg), group B (0.125 mg), and group C (0.250 mg). A significant increment of total sleep time, sleep efficiency and a reduction of wake after sleep onset, number of awakening and non-REM sleep stage 1 was observed in T1 (triazolam) in comparison to T0 (placebo) by means of polysomnographic recording, irrespective of dosage. After 2 weeks of the treatment, insomnia severity significantly improved in all three groups in comparison to baseline without diurnal residual effects. This study demonstrates that low dose of triazolam objectively and subjectively improves the sleep of patients having MOTN insomnia.
Subject(s)
Hypnotics and Sedatives/administration & dosage , Sleep Initiation and Maintenance Disorders/drug therapy , Triazolam/administration & dosage , Adult , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Middle Aged , Polysomnography , Psychomotor Performance/drug effects , Severity of Illness Index , Sleep/drug effects , Sleep Initiation and Maintenance Disorders/physiopathology , Treatment Outcome , Young AdultSubject(s)
Anesthesia, Dental/standards , Conscious Sedation/standards , Hypnotics and Sedatives/therapeutic use , Triazolam/therapeutic use , Adult , Anesthesia, Dental/methods , Conscious Sedation/methods , Humans , Hypnotics and Sedatives/administration & dosage , Practice Guidelines as Topic , Societies, Dental/standards , Triazolam/administration & dosage , United StatesABSTRACT
We have previously reported an anxiolytic-sensitive human EEG biomarker, goal conflict specific rhythmicity (GCSR), using an auditory stop signal task (SST). Here we test if a visual SST could allow testing of GCSR in people with hearing impairments. The visual SST produced GCSR within the 4-12Hz band at the expected right frontal site, F8, but to a lesser extent than in previous auditory SSTs, possibly due to response instability. Positive GCSR appeared to be reduced by both buspirone (10mg), and triazolam (0.25mg), as previously; negative GCSR was increased. However, neuroticism, trait anxiety and Behavioural Inhibition System scores failed to show consistent positive correlations with GCSR, contrary to prediction. The visual SST generates anxiolytic-sensitive GCSR; but its limited extent and unexpected personality correlations suggest it needs further development to obtain quantitative equivalence with the auditory SST.
Subject(s)
Anti-Anxiety Agents/pharmacology , Anxiety/physiopathology , Auditory Perception/physiology , Brain Waves/physiology , Cerebral Cortex/physiology , Conflict, Psychological , Inhibition, Psychological , Visual Perception/physiology , Adolescent , Adult , Anti-Anxiety Agents/administration & dosage , Auditory Perception/drug effects , Biomarkers , Brain Waves/drug effects , Buspirone/administration & dosage , Buspirone/pharmacology , Cerebral Cortex/drug effects , Female , Humans , Male , Triazolam/administration & dosage , Triazolam/pharmacology , Visual Perception/drug effects , Young AdultABSTRACT
OBJECTIVE: Next-day residual effects of a nighttime dose of gabapentin 250 mg were evaluated on simulated driving performance in healthy participants in a randomized, placebo-controlled, double-blind, multicenter, four-period crossover study that included diphenhydramine citrate 76 mg and triazolam 0.5 mg. METHODS: At treatment visits, participants (n = 59) were dosed at ~23:30, went to bed immediately, and awakened 6.5 h postdose for evaluation. The primary endpoint was the standard deviation of lateral position for the 100-km driving scenario. Additional measures of driving, sleepiness, and cognition were included. RESULTS: Study sensitivity was established with triazolam, which demonstrated significant next-day impairment on all driving endpoints, relative to placebo (p < 0.001). Gabapentin demonstrated noninferiority to placebo on standard deviation of lateral position and speed deviation but not for lane excursions. Diphenhydramine citrate demonstrated significant impairment relative to gabapentin and placebo on speed deviation (p < 0.05). Other comparisons were either nonsignificant or statistically ineligible per planned, sequential comparisons. Secondary endpoints for sleepiness and cognitive performance were supportive of these conclusions. CONCLUSIONS: Together, these data suggest that low-dose gabapentin had no appreciable next-day effects on simulated driving performance or cognitive functioning. Copyright © 2016 John Wiley & Sons, Ltd.
Subject(s)
Amines/adverse effects , Automobile Driving , Cyclohexanecarboxylic Acids/adverse effects , Diphenhydramine/adverse effects , Triazolam/adverse effects , gamma-Aminobutyric Acid/adverse effects , Adult , Amines/administration & dosage , Analgesics/administration & dosage , Analgesics/adverse effects , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/adverse effects , Cognition/drug effects , Cross-Over Studies , Cyclohexanecarboxylic Acids/administration & dosage , Diphenhydramine/administration & dosage , Double-Blind Method , Female , Gabapentin , Humans , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/adverse effects , Male , Middle Aged , Sleep Stages/drug effects , Time Factors , Triazolam/administration & dosage , gamma-Aminobutyric Acid/administration & dosageABSTRACT
BACKGROUND: Conventional benzodiazepines bind non-selectively to GABAA receptors containing α1, α2, α3, and α5 subunits (α1GABAA, α2GABAA, α3GABAA, and α5GABAA receptors, respectively), and the role of these different GABAA receptor subtypes in the reinforcing effects of benzodiazepines has not been characterized fully. We used a pharmacological antagonist approach with available subtype-selective ligands to evaluate the role of GABAA receptor subtypes in the reinforcing effects of the non-selective conventional benzodiazepine, triazolam. METHODS: Rhesus monkeys (n=4) were trained under a progressive-ratio schedule of intravenous midazolam delivery and dose-response functions were determined for triazolam, in the absence and presence of flumazenil (non-selective antagonist), ßCCT and 3-PBC (α1GABAA-preferring antagonists), and XLi-093 (α5GABAA-selective antagonist). RESULTS: Flumazenil, ßCCT and 3-PBC shifted the dose-response functions for triazolam to the right in a surmountable fashion, whereas XLi-093 was ineffective. Schild analyses revealed rank orders of potencies of flumazenil=ßCCT>3-PBC. Comparison of potencies between self-administration and previous binding studies with human cloned GABAA receptor subtypes suggested that the potencies for ßCCT and 3-PBC were most consistent with binding at α2GABAA and α3GABAA receptors, but not α1GABAA or α5GABAA receptor subtypes. CONCLUSIONS: Our findings were not entirely consistent with blockade of α1GABAA receptors and are consistent with the possibility of α2GABAA and/or α3GABAA subtype involvement in antagonism of the reinforcing effects of triazolam. The α5GABAA receptor subtype likely does not play a substantial role in self-administration under these conditions.
Subject(s)
Reaction Time/drug effects , Reinforcement Schedule , Triazolam/administration & dosage , Triazolam/antagonists & inhibitors , Animals , Benzodiazepines/administration & dosage , Dose-Response Relationship, Drug , GABA Modulators/administration & dosage , GABA Modulators/antagonists & inhibitors , Humans , Macaca mulatta , Male , Midazolam/administration & dosage , Reaction Time/physiology , Receptors, GABA-A/metabolism , Self AdministrationSubject(s)
Anesthesia, Dental , Conscious Sedation , Informed Consent/legislation & jurisprudence , Patient Safety/legislation & jurisprudence , Adjuvants, Anesthesia/administration & dosage , Anesthetics, Inhalation/administration & dosage , Humans , Nitrous Oxide/administration & dosage , Triazolam/administration & dosageABSTRACT
Benzodiazepines are positive allosteric modulators of the GABAA receptor and are prescribed as anxiolytics, hypnotics, and anticonvulsants. While these drugs clearly have clinical value, their use is associated with unwanted side effects such as sedation and motor impairment. Neuroactive steroids are endogenous modulators of GABAA receptors and recent evidence has shown that combinations of the triazolo-benzodiazepine triazolam and the endogenous neuroactive steroid pregnanolone can produce both supra-additive anxiolytic effects and infra-additive reinforcing effects. In the present study, we investigated these same combinations as well as combinations of two clinically-relevant drugs from different chemical classes, the 1, 4 substituted (7-nitro) benzodiazepine clonazepam and the synthetic neuroactive steroid ganaxolone, in rats trained under a 10-response, fixed ratio (FR) schedule of food reinforcement. All four drugs induced a significant and dose-dependent suppression of food-maintained responding. From the dose-response functions, ED50s (i.e., the doses that engendered 50% of the maximum rate-decreasing effect) were generated for each drug. Dose-response functions for combinations of triazolam/pregnanolone, clonazepam/ganaxolone, triazolam/ganaxolone, and clonazepam/pregnanolone were then determined. Isobolographic analysis of the rate-decreasing effects of these combinations revealed that the potencies of the triazolam/pregnanolone combinations were supra-additive while the clonazepam/ganaxolone combinations were additive or infra-additive in relation to predicted values based on dose-additive effects. Furthermore, mixtures of clonazepam/pregnanolone were supra-additive while triazolam/ganaxolone combinations were additive, infra-additive and supra-additive. These results suggest that the ability of benzodiazepine and neuroactive steroid combinations to attenuate rates of food-maintained responding depends critically on both the constituent drugs and the dose of drug in the mixtures.
Subject(s)
Benzodiazepines/administration & dosage , GABA Modulators/administration & dosage , Pregnanolone/administration & dosage , Reaction Time/drug effects , Reinforcement Schedule , Steroids/administration & dosage , Animals , Dose-Response Relationship, Drug , Drug Combinations , Male , Pregnanolone/analogs & derivatives , Rats , Rats, Sprague-Dawley , Reaction Time/physiology , Triazolam/administration & dosageABSTRACT
Along with urbanization of the living environment, the number of patients with circadian rhythm sleep disorder (CRSD) has been increasing. There are several treatment candidates for CRSD, such as light therapy, drugs (melatonin and vitamin B12), and sleep hygiene education. However, successful treatment method has not been established. In free-running type (FRT) CRSD, the endogenous circadian rhythm cannot be entrained to the 24-h light-dark cycle, resulting in free running on a cycle 0.5-2.5 h longer than the 24-h period. This condition is relatively common in blind individuals and is unusual in sighted individuals. Here we report two sighted patients with FRT, successfully treated with a melatonin receptor agonist, ramelteon. Patient 1 (36-year-old female) had suffered from FRT for nearly 4 months after resigning her job. She was given sleep hygiene education together with ramelteon at first and the free-running cycle stopped after treatment day 15. Triazolam was added from the day 25 to promote earlier sleep onset. And the sleep-wake schedule was normalized by the day 34. Patient 2 (33-year-old male) had suffered from FRT for nearly 8 months after starting to take a leave of absence from his job. He was given sleep hygiene education and was treated with ramelteon and methylcobalamin. His sleep-wake schedule was normalized from the first treatment day. By the combined treatment with ramelteon, both patients have maintained favorable sleep-wake schedules. The agonist action of ramelteon at the melatonin 2 receptor may have primarily contributed to the cessation of the free-running cycle in these patients.
Subject(s)
Receptors, Melatonin/agonists , Sleep Disorders, Circadian Rhythm , Adult , Circadian Rhythm , Drug Therapy, Combination , Female , Humans , Indenes/administration & dosage , Male , Sleep , Treatment Outcome , Triazolam/administration & dosage , Vitamin B 12/administration & dosage , Vitamin B 12/analogs & derivatives , WakefulnessSubject(s)
Conscious Sedation/methods , Drug Overdose/etiology , Hypnotics and Sedatives/administration & dosage , Adjuvants, Anesthesia/administration & dosage , Adjuvants, Anesthesia/poisoning , Age Factors , Anesthetics, Local/administration & dosage , Anesthetics, Local/poisoning , Dose-Response Relationship, Drug , Drug Interactions , Drug Labeling , Female , Humans , Hypnotics and Sedatives/poisoning , Lidocaine/administration & dosage , Lidocaine/poisoning , Male , Risk Assessment , Sex Factors , Sleep Apnea, Obstructive/physiopathology , Triazolam/administration & dosage , Triazolam/poisoning , United States , United States Food and Drug AdministrationABSTRACT
BACKGROUND: Although concerns surrounding high-dose dextromethorphan (DXM) abuse have recently increased, few studies have examined the acute cognitive effects of high doses of DXM. The aim of this study was to compare the cognitive effects of DXM with those of triazolam and placebo. METHODS: Single, acute, oral doses of DXM (100, 200, 300, 400, 500, 600, 700, 800 mg/70 kg), triazolam (0.25, 0.5mg/70 kg), and placebo were administered p.o. to twelve healthy volunteers with histories of hallucinogen use, under double-blind conditions, using an ascending dose run-up design. Effects on cognitive performance were examined at baseline and after drug administration for up to 6h. RESULTS: Both triazolam and DXM produced acute impairments in attention, working memory, episodic memory, and metacognition. Impairments observed following doses of 100-300 mg/70 kg DXM were generally smaller in magnitude than those observed after 0.5mg/70 kg triazolam. Doses of DXM that impaired performance to the same extent as triazolam were in excess of 10-30 times the therapeutic dose of DXM. CONCLUSION: The magnitude of the doses required for these effects and the absence of effects on some tasks within the 100-300 mg/70 kg dose range of DXM, speak to the relatively broad therapeutic window of over-the-counter DXM preparations when used appropriately. However, the administration of supratherapeutic doses of DXM resulted in acute cognitive impairments on all tasks that were examined. These findings are likely relevant to cases of high-dose DXM abuse.
Subject(s)
Cognition/drug effects , Dextromethorphan/adverse effects , Hypnotics and Sedatives/pharmacology , Triazolam/adverse effects , Adult , Analysis of Variance , Dextromethorphan/administration & dosage , Dose-Response Relationship, Drug , Double-Blind Method , Hallucinogens/adverse effects , Humans , Male , Neuropsychological Tests , Triazolam/administration & dosageABSTRACT
RATIONALE: Several studies have documented impairments in memory processes as a result of ketamine administration; however, few studies have compared the profile of cognitive effects of ketamine to other drugs. OBJECTIVES: The aim of this study was to compare the cognitive effects of ketamine with those of triazolam in healthy volunteers. METHODS: Doses of ketamine (0.2, 0.4 mg/kg intramuscular (i.m.)), triazolam (0.2, 0.4 mg/70 kg p.o.), and double-dummy placebos were administered to 20 volunteers under repeated measures, counterbalanced, double-blind conditions. Peak physiological, psychomotor, subjective, and cognitive effects were examined. RESULTS: Ketamine impaired balance when balance was assessed early in the task order, whereas triazolam impaired psychomotor coordination and divided attention irrespective of task order. Triazolam also tended to produce greater effects on working memory and episodic memory tasks than ketamine at doses that produced lower subjective effects and higher estimates of performance. CONCLUSIONS: Ketamine produces less cognitive impairment than triazolam at doses that produced greater subjective effects. Thus ketamine does not produce the underestimation of cognitive impairment typically seen with triazolam.
Subject(s)
Adjuvants, Anesthesia/adverse effects , Anesthetics, Dissociative/adverse effects , Cognition/drug effects , Ketamine/adverse effects , Triazolam/adverse effects , Adjuvants, Anesthesia/administration & dosage , Administration, Oral , Adult , Anesthetics, Dissociative/administration & dosage , Cognition Disorders/chemically induced , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Injections, Intramuscular , Ketamine/administration & dosage , Male , Memory, Short-Term/drug effects , Psychomotor Performance/drug effects , Triazolam/administration & dosage , Young AdultABSTRACT
OBJECTIVE: The objective of this study was to evaluate the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam. METHODS: In this randomized, cross-over study, 12 healthy volunteers received a single oral dose of triazolam 0.25 mg alone or with AST-120 2 g given 0, 30 or 60 min before triazolam administration. RESULTS: The area under the plasma triazolam concentration-time curve (AUC(0-∞)) significantly decreased with simultaneous AST-120 + triazolam (alone vs simultaneous: 10.9 ± 6.0 vs 6.4 ± 2.6 ng·h/mL, p = 0.003). Triazolam-induced impairment in psychomotor performance assessed by the digit symbol substitution test was significantly attenuated when AST-120 was administered simultaneously. No significant changes in pharmacokinetic and pharmacodynamic parameters were observed when AST-120 was given 30 or 60 min before triazolam administration. CONCLUSIONS: Administering AST-120 simultaneously with triazolam affects the pharmacokinetics and pharmacodynamics of triazolam. Dosing AST-120 at least 30 min before triazolam administration may avoid these interactions.
Subject(s)
Carbon/administration & dosage , Hypnotics and Sedatives/administration & dosage , Oxides/administration & dosage , Triazolam/administration & dosage , Adsorption , Adult , Area Under Curve , Carbon/pharmacokinetics , Cross-Over Studies , Drug Administration Schedule , Drug Interactions , Female , Humans , Hypnotics and Sedatives/blood , Hypnotics and Sedatives/pharmacokinetics , Male , Oxides/pharmacokinetics , Triazolam/blood , Triazolam/pharmacokinetics , Young AdultABSTRACT
RATIONALE: Although reports of dextromethorphan (DXM) abuse have increased recently, few studies have examined the effects of high doses of DXM. OBJECTIVE: This study in humans evaluated the effects of supratherapeutic doses of DXM and triazolam. METHODS: Single, acute oral doses of DXM (100, 200, 300, 400, 500, 600, 700, and 800 mg/70 kg), triazolam (0.25 and 0.5 mg/70 kg), and placebo were administered to 12 healthy volunteers with histories of hallucinogen use, under double-blind conditions, using an ascending dose run-up design. Subjective, behavioral, and physiological effects were assessed repeatedly after drug administration for 6 h. RESULTS: Triazolam produced dose-related increases in subject-rated sedation, observer-rated sedation, and behavioral impairment. DXM produced a profile of dose-related physiological and subjective effects differing from triazolam. DXM effects included increases in blood pressure, heart rate, and emesis; increases in observer-rated effects typical of classic hallucinogens (e.g., distance from reality, visual effects with eyes open and closed, joy, anxiety); and participant ratings of stimulation (e.g., jittery, nervous), somatic effects (e.g., tingling, headache), perceptual changes, end-of-session drug liking, and mystical-type experience. After 400 mg/70 kg DXM, 11 of 12 participants indicated on a pharmacological class questionnaire that they thought they had received a classic hallucinogen (e.g., psilocybin). Drug effects resolved without significant adverse effects by the end of the session. In a 1-month follow-up, volunteers attributed increased spirituality and positive changes in attitudes, moods, and behavior to the session experiences. CONCLUSIONS: High doses of DXM produced effects distinct from triazolam and had characteristics that were similar to the classic hallucinogen psilocybin.
Subject(s)
Dextromethorphan/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , GABA Modulators/pharmacology , Triazolam/pharmacology , Adult , Affect/drug effects , Attitude , Dextromethorphan/administration & dosage , Dose-Response Relationship, Drug , Double-Blind Method , Excitatory Amino Acid Antagonists/administration & dosage , Female , Follow-Up Studies , GABA Modulators/administration & dosage , Hallucinogens/pharmacology , Humans , Male , Psilocybin/pharmacology , Surveys and Questionnaires , Triazolam/administration & dosage , Young AdultSubject(s)
Antineoplastic Agents/poisoning , Piperazines/poisoning , Pyrimidines/poisoning , Suicide, Attempted , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Azepines/administration & dosage , Azepines/poisoning , Benzamides , Drug Overdose , Female , Humans , Imatinib Mesylate , Leukemia, Myeloid, Chronic-Phase/drug therapy , Middle Aged , Piperazines/administration & dosage , Piperazines/pharmacokinetics , Pyrimidines/administration & dosage , Pyrimidines/pharmacokinetics , Triazolam/administration & dosage , Triazolam/poisoningABSTRACT
There is accumulating evidence that sex plays a critical role in drug abuse. Female sex hormones have been shown to affect central nervous system function and modulate the effects of drugs of abuse. For example, γ-aminobutyric acid type A (GABA(A)) receptor function is positively modulated by progesterone metabolites. There is evidence from preclinical in-vitro and in-vivo studies as well as some clinical research suggesting that progesterone and its metabolites may enhance the behavioral effects of benzodiazepines, which also serve as positive modulators of GABA(A) receptors. The purpose of this experiment was to determine the independent and combined discriminative stimulus, subjective and psychomotor effects of progesterone and triazolam in healthy adult premenopausal women. Oral micronized progesterone (100 mg), triazolam (0.06, 0.12 and 0.25 mg/70 kg) and placebo were administered to healthy, premenopausal women (n=9) under conditions of low circulating sex hormones. Triazolam alone functioned as a discriminative stimulus and produced prototypical sedative-like effects (e.g., performance impairment, enhanced reports of sedative effects). Progesterone alone produced sedative-like effects on several subjective and performance measures, and the dose combination effects of progesterone and triazolam on several subjective measures of drug effect were similar to the summation of the two drug effects in isolation. Progesterone did not substitute for or modify the discriminative stimulus effects of triazolam. These results suggest that the parent hormone, progesterone, and triazolam have discordant neuropharmacological mechanisms of action. Additional research is necessary to determine the degree to which neurosteroids influence sex differences in benzodiazepine use and abuse.